ITUS Will Hold Conference Call to Discuss its CAR-T Cancer Therapeutics Program
SAN JOSE, Calif., Nov. 21, 2017 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS) reminds interested parties that it will be holding a conference call today at 2 p.m. Pacific/5 p.m. Eastern to discuss the launch of its Chimeric Antigen Receptor T-Cell (CAR-T) cancer therapeutics program.
After licensing CAR-T technology developed at The Wistar Institute, ITUS entered into a collaboration with the Moffitt Cancer Center, to advance toward human clinical testing, the CAR-T technology aimed initially at Ovarian Cancer, and eventually additional solid tumors.
Dr. Amit Kumar, President and CEO of ITUS will host the call. To access the call, please dial (866) 966-5335 five minutes prior to the start time. A replay of the call will be available at www.ITUScorp.com for 10 days after the call.
ITUS, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer. Its wholly owned subsidiary, Anixa Diagnostics Corporation, is developing the Cchek™ platform, a series of non-invasive blood tests for the early detection of solid tumor based cancers, which is based on the body's immunological response to the presence of a malignancy. Its majority owned subsidiary, Certainty Therapeutics, Inc., is developing CAR-T based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. ITUS also continually examines emerging technologies in complementary or related fields for further development and commercialization. Additional information is available at www.ITUScorp.com.
Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect ITUS Corporation's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A – Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
ITUS Corporation: FOCUSED ON INNOVATION™
View original content with multimedia:http://www.prnewswire.com/news-releases/itus-will-hold-conference-call-to-discuss-its-car-t-cancer-therapeutics-program-300560362.html
SOURCE ITUS Corporation
Released November 21, 2017
Sign up for email Updates
Be The First to Receive Breaking NewsSign Up Now